List of Excipients in API bictegravir sodium, emtricitabine, and tenofovir alafenamide fumarate
✉ Email this page to a colleague
Excipients in NDA-approved (novel) drugs containing bictegravir sodium, emtricitabine, and tenofovir alafenamide fumarate
| Company | Tradename | Ingredient | NDC | Excipient | Potential Generic Entry |
|---|---|---|---|---|---|
| A-S Medication Solutions | BIKTARVY | bictegravir sodium, emtricitabine, and tenofovir alafenamide fumarate | 50090-6247 | CELLULOSE, MICROCRYSTALLINE | 2036-11-08 |
| A-S Medication Solutions | BIKTARVY | bictegravir sodium, emtricitabine, and tenofovir alafenamide fumarate | 50090-6247 | CROSCARMELLOSE SODIUM | 2036-11-08 |
| A-S Medication Solutions | BIKTARVY | bictegravir sodium, emtricitabine, and tenofovir alafenamide fumarate | 50090-6247 | FERRIC OXIDE RED | 2036-11-08 |
| A-S Medication Solutions | BIKTARVY | bictegravir sodium, emtricitabine, and tenofovir alafenamide fumarate | 50090-6247 | FERROSOFERRIC OXIDE | 2036-11-08 |
| >Company | >Tradename | >Ingredient | >NDC | >Excipient | >Potential Generic Entry |
Detailed excipient profiles for bictegravir sodium, emtricitabine, and tenofovir alafenamide fumarate
Excipient focus: CELLULOSE, MICROCRYSTALLINE
bictegravir sodium, emtricitabine, and tenofovir alafenamide fumarate drug variants containing CELLULOSE, MICROCRYSTALLINE
bictegravir sodium, emtricitabine, and tenofovir alafenamide fumarate drug variants not containing CELLULOSE, MICROCRYSTALLINE
| Company | Ingredient | NDC |
|---|---|---|
| >Company | >Ingredient | >NDC |
Excipient focus: CROSCARMELLOSE SODIUM
bictegravir sodium, emtricitabine, and tenofovir alafenamide fumarate drug variants containing CROSCARMELLOSE SODIUM
bictegravir sodium, emtricitabine, and tenofovir alafenamide fumarate drug variants not containing CROSCARMELLOSE SODIUM
| Company | Ingredient | NDC |
|---|---|---|
| >Company | >Ingredient | >NDC |
Excipient focus: FERRIC OXIDE RED
bictegravir sodium, emtricitabine, and tenofovir alafenamide fumarate drug variants containing FERRIC OXIDE RED
bictegravir sodium, emtricitabine, and tenofovir alafenamide fumarate drug variants not containing FERRIC OXIDE RED
| Company | Ingredient | NDC |
|---|---|---|
| >Company | >Ingredient | >NDC |
Excipient focus: FERROSOFERRIC OXIDE
bictegravir sodium, emtricitabine, and tenofovir alafenamide fumarate drug variants containing FERROSOFERRIC OXIDE
bictegravir sodium, emtricitabine, and tenofovir alafenamide fumarate drug variants not containing FERROSOFERRIC OXIDE
| Company | Ingredient | NDC |
|---|---|---|
| >Company | >Ingredient | >NDC |
Excipient focus: MAGNESIUM STEARATE
bictegravir sodium, emtricitabine, and tenofovir alafenamide fumarate drug variants containing MAGNESIUM STEARATE
bictegravir sodium, emtricitabine, and tenofovir alafenamide fumarate drug variants not containing MAGNESIUM STEARATE
| Company | Ingredient | NDC |
|---|---|---|
| >Company | >Ingredient | >NDC |
Excipient focus: POLYETHYLENE GLYCOL
bictegravir sodium, emtricitabine, and tenofovir alafenamide fumarate drug variants containing POLYETHYLENE GLYCOL
bictegravir sodium, emtricitabine, and tenofovir alafenamide fumarate drug variants not containing POLYETHYLENE GLYCOL
| Company | Ingredient | NDC |
|---|---|---|
| >Company | >Ingredient | >NDC |
Excipient focus: POLYVINYL ALCOHOL
bictegravir sodium, emtricitabine, and tenofovir alafenamide fumarate drug variants containing POLYVINYL ALCOHOL
bictegravir sodium, emtricitabine, and tenofovir alafenamide fumarate drug variants not containing POLYVINYL ALCOHOL
| Company | Ingredient | NDC |
|---|---|---|
| >Company | >Ingredient | >NDC |
Excipient focus: TALC
bictegravir sodium, emtricitabine, and tenofovir alafenamide fumarate drug variants containing TALC
bictegravir sodium, emtricitabine, and tenofovir alafenamide fumarate drug variants not containing TALC
| Company | Ingredient | NDC |
|---|---|---|
| >Company | >Ingredient | >NDC |
Excipient focus: TITANIUM DIOXIDE
bictegravir sodium, emtricitabine, and tenofovir alafenamide fumarate drug variants containing TITANIUM DIOXIDE
bictegravir sodium, emtricitabine, and tenofovir alafenamide fumarate drug variants not containing TITANIUM DIOXIDE
| Company | Ingredient | NDC |
|---|---|---|
| >Company | >Ingredient | >NDC |
Excipient focus: WATER
bictegravir sodium, emtricitabine, and tenofovir alafenamide fumarate drug variants containing WATER
bictegravir sodium, emtricitabine, and tenofovir alafenamide fumarate drug variants not containing WATER
| Company | Ingredient | NDC |
|---|---|---|
| >Company | >Ingredient | >NDC |
Make Better Decisions: Try a trial or see plans & pricing
Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.
ISSN: 2162-2639
Privacy and Cookies
Terms & Conditions
Site Map
DrugPatentWatch Alternatives
LOE / Generic Entry Opportunies 2024 - 2025
NCE-1 Patent Challenge Dates 2024 - 2025
Trigger-based marketing for the life sciences
Get DrugPatentWatch Business Intelligence Reports at Amazon.com
DrugChatter - AI-based answers to questions about drugs
RxJam - HIPAA-ready chat for life sciences
Friedman, Yali. "DrugPatentWatch" DrugPatentWatch, thinkBiotech, 2024, www.DrugPatentWatch.com.
See Primary Research Papers Citing DrugPatentWatch
Follow DrugPatentWatch:
